Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
29.15 (1y: +32%)
Market Cap 203.1 B P/E(ttm) 13.90
Enterprise Value 209.21 B P/B 2.60
PFE- NYSE (USA)
Pfizer Inc
  • Currently 3/5
Business Predictability Rank: 3-Star (On Watch)
Back Testing Results:
Average gain of all 3-Star stocks: 8.2% per year.
% of Stocks that are in still loss if held for 10yrs: 11%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$29.15
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 0.873
PFE's Cash to Debt is ranked lower than
70% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.36 vs. PFE: 0.873 )
PFE' s 10-Year Cash to Debt Range
Min: 0.48   Max: 3.47
Current: 0.87
0.48
3.47
Equity to Asset -0.051
PFE's Equity to Asset is ranked lower than
92% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.52 vs. PFE: -0.051 )
PFE' s 10-Year Equity to Asset Range
Min: -0.1   Max: 0.44
Current: -0.05
-0.1
0.44
Interest Coverage 10.6
PFE's Interest Coverage is ranked lower than
74% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10000.00 vs. PFE: 10.6 )
PFE' s 10-Year Interest Coverage Range
Min: 7   Max: 14760
Current: 10.6
7
14760
Z-Score: 2.2
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 20.50
PFE's Operating margin (%) is ranked higher than
93% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.70 vs. PFE: 20.50 )
PFE' s 10-Year Operating margin (%) Range
Min: 10.4   Max: 36
Current: 20.5
10.4
36
Net-margin (%) 24.7
PFE's Net-margin (%) is ranked higher than
92% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. PFE: 24.7 )
PFE' s 10-Year Net-margin (%) Range
Min: 8.7   Max: 40
Current: 24.7
8.7
40
ROE (%) 17.9
PFE's ROE (%) is ranked higher than
83% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. PFE: 17.9 )
PFE' s 10-Year ROE (%) Range
Min: 6   Max: 45.7
Current: 17.9
6
45.7
ROA (%) 7.8
PFE's ROA (%) is ranked higher than
74% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. PFE: 7.8 )
PFE' s 10-Year ROA (%) Range
Min: 3.3   Max: 19.9
Current: 7.8
3.3
19.9
ROC (Joel Greenblatt) (%) 57.60
PFE's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.40 vs. PFE: 57.60 )
PFE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 22.1   Max: 89.2
Current: 57.6
22.1
89.2
Revenue Growth (%) 2.6
PFE's Revenue Growth (%) is ranked higher than
83% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. PFE: 2.6 )
PFE' s 10-Year Revenue Growth (%) Range
Min: 0.3   Max: 10.3
Current: 2.6
0.3
10.3
EBITDA Growth (%) 4.3
PFE's EBITDA Growth (%) is ranked higher than
88% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.35 vs. PFE: 4.3 )
PFE' s 10-Year EBITDA Growth (%) Range
Min: -8.5   Max: 18.8
Current: 4.3
-8.5
18.8
EPS Growth (%) 12.1
PFE's EPS Growth (%) is ranked higher than
73% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. PFE: 12.1 )
PFE' s 10-Year EPS Growth (%) Range
Min: -17.5   Max: 49
Current: 12.1
-17.5
49
ยป PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

PFE Guru Trades in Q2 2012

Ray Dalio 98,600 sh (New)
Andreas Halvorsen 6,809,900 sh (New)
Manning & Napier Advisors, Inc 947,637 sh (+88.3%)
Steven Cohen 179,479 sh (+13.71%)
Jean-Marie Eveillard 4,142,361 sh (+6.79%)
Mario Gabelli 1,471,204 sh (+5.3%)
Diamond Hill Capital 9,813,993 sh (+4.11%)
Pioneer Investments 9,915,283 sh (+3.24%)
RS Investment Management 2,923,755 sh (+1.25%)
Bill Frels 2,609,369 sh (+0.09%)
Robert Bruce 430,000 sh (unchged)
Alan Fournier 2,806,574 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Ruane Cunniff 9,215 sh (unchged)
Vanguard Health Care Fund 38,083,888 sh (unchged)
Michael Price 702,100 sh (unchged)
Tom Russo 1,900 sh (unchged)
Lee Ainslie Sold Out
Richard Perry Sold Out
Irving Kahn 2,512,819 sh (-0.04%)
Ken Fisher 22,158,251 sh (-0.05%)
Donald Yacktman 17,578,694 sh (-0.12%)
Jeff Auxier 179,457 sh (-0.39%)
Ronald Muhlenkamp 358,754 sh (-0.6%)
Jeremy Grantham 62,990,583 sh (-0.95%)
Murray Stahl 58,991 sh (-1.14%)
James Barrow 59,179,007 sh (-2.65%)
John Keeley 111,855 sh (-3.45%)
HOTCHKIS & WILEY 5,661,332 sh (-3.55%)
Dodge & Cox 76,336,361 sh (-10.75%)
NWQ Managers 26,792,614 sh (-11.11%)
Joel Greenblatt 31,775 sh (-11.94%)
Chris Davis 3,283,157 sh (-15.22%)
David Dreman 733,714 sh (-17.75%)
Charles Brandes 9,367,718 sh (-21.64%)
George Soros 538,457 sh (-32.27%)
Mark Hillman 119,662 sh (-47.77%)
John Hussman 1,001,000 sh (-49.98%)
Richard Snow 514,980 sh (-71.01%)
Paul Tudor Jones 147,800 sh (-82.96%)
» More
Q3 2012

PFE Guru Trades in Q3 2012

Paul Tudor Jones 407,500 sh (+175.71%)
Steven Cohen 341,140 sh (+90.07%)
Pioneer Investments 16,120,569 sh (+62.58%)
Ken Fisher 32,041,849 sh (+44.6%)
Joel Greenblatt 44,666 sh (+40.57%)
Manning & Napier Advisors, Inc 1,018,669 sh (+7.5%)
John Keeley 112,075 sh (+0.2%)
Brian Rogers 12,287,115 sh (unchged)
Alan Fournier 2,806,574 sh (unchged)
Murray Stahl 58,991 sh (unchged)
Yacktman Fund 7,800,000 sh (unchged)
Tom Russo 1,900 sh (unchged)
Paul Tudor Jones 1,000,000 sh (unchged)
Ruane Cunniff 9,215 sh (unchged)
Robert Bruce 430,000 sh (unchged)
Yacktman Focused Fund 5,600,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
John Hussman Sold Out
Signature Select Canadian Fund Sold Out
Mark Hillman Sold Out
Andreas Halvorsen Sold Out
Jean-Marie Eveillard 4,138,361 sh (-0.1%)
Bill Frels 2,606,031 sh (-0.13%)
Donald Yacktman 17,551,712 sh (-0.15%)
James Barrow 59,052,000 sh (-0.21%)
Ronald Muhlenkamp 357,049 sh (-0.48%)
Irving Kahn 2,483,606 sh (-1.16%)
Vanguard Health Care Fund 37,383,888 sh (-1.84%)
Dodge & Cox 74,653,759 sh (-2.2%)
Diamond Hill Capital 9,512,648 sh (-3.07%)
Chris Davis 3,154,139 sh (-3.93%)
Jeremy Grantham 60,337,454 sh (-4.21%)
Jeff Auxier 170,057 sh (-5.24%)
Michael Price 657,100 sh (-6.41%)
HOTCHKIS & WILEY 5,205,478 sh (-8.05%)
Charles Brandes 8,407,621 sh (-10.25%)
RS Investment Management 2,559,621 sh (-12.45%)
Mario Gabelli 1,285,231 sh (-12.64%)
NWQ Managers 21,105,016 sh (-21.23%)
David Dreman 483,957 sh (-34.04%)
Ray Dalio 45,200 sh (-54.16%)
George Soros 165,000 sh (-69.36%)
Richard Snow 95,632 sh (-81.43%)
» More
Q4 2012

PFE Guru Trades in Q4 2012

Jim Simons 969,541 sh (New)
Ray Dalio 78,400 sh (+73.45%)
Steven Cohen 549,639 sh (+61.12%)
RS Investment Management 2,772,752 sh (+8.33%)
Joel Greenblatt 46,557 sh (+4.23%)
Murray Stahl 59,487 sh (+0.84%)
Jean-Marie Eveillard 4,158,761 sh (+0.49%)
Robert Bruce 432,000 sh (+0.47%)
Manning & Napier Advisors, Inc 1,022,217 sh (+0.35%)
Ruane Cunniff 9,215 sh (unchged)
Michael Price 657,100 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Tom Russo 1,900 sh (unchged)
Yacktman Fund 7,800,000 sh (unchged)
George Soros 165,000 sh (unchged)
Jeremy Grantham 51,935,078 sh (unchged)
Yacktman Focused Fund 5,600,000 sh (unchged)
Vanguard Health Care Fund 33,383,888 sh (unchged)
Paul Tudor Jones Sold Out
Bill Frels 2,602,056 sh (-0.15%)
Irving Kahn 2,468,814 sh (-0.6%)
Ken Fisher 31,773,208 sh (-0.84%)
Jeff Auxier 167,712 sh (-1.38%)
James Barrow 57,986,630 sh (-1.8%)
Richard Snow 93,094 sh (-2.65%)
Mario Gabelli 1,236,761 sh (-3.77%)
Dodge & Cox 71,247,670 sh (-4.56%)
Donald Yacktman 16,707,327 sh (-4.81%)
John Keeley 105,710 sh (-5.68%)
Pioneer Investments 15,172,045 sh (-5.88%)
Diamond Hill Capital 8,911,007 sh (-6.32%)
Chris Davis 2,835,580 sh (-10.1%)
Vanguard Health Care Fund 33,383,888 sh (-10.7%)
Charles Brandes 7,287,838 sh (-13.32%)
HOTCHKIS & WILEY 3,881,826 sh (-25.43%)
NWQ Managers 15,439,664 sh (-26.84%)
Alan Fournier 1,906,574 sh (-32.07%)
David Dreman 110,998 sh (-77.06%)
Ronald Muhlenkamp 37,624 sh (-89.46%)
» More
Q1 2013

PFE Guru Trades in Q1 2013

Bruce Kovner 240,000 sh (New)
Paul Tudor Jones 1,827,050 sh (New)
Jean-Marie Eveillard 6,562,712 sh (+57.8%)
Joel Greenblatt 54,322 sh (+16.68%)
Manning & Napier Advisors, Inc 1,098,977 sh (+7.51%)
Jeremy Grantham 55,724,978 sh (+7.3%)
Richard Snow 97,014 sh (+4.21%)
Irving Kahn 2,572,436 sh (+4.2%)
Jeff Auxier 169,859 sh (+1.28%)
Bill Frels 2,623,103 sh (+0.81%)
James Barrow 58,282,831 sh (+0.51%)
Yacktman Focused Fund 5,600,000 sh (unchged)
Robert Bruce 432,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Yacktman Fund 7,800,000 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
George Soros 165,000 sh (unchged)
Tom Russo 1,900 sh (unchged)
Jim Simons Sold Out
Chris Davis Sold Out
Ruane Cunniff 9,147 sh (-0.74%)
Murray Stahl 58,930 sh (-0.94%)
Diamond Hill Capital 8,820,065 sh (-1.02%)
John Keeley 104,425 sh (-1.22%)
Dodge & Cox 69,759,556 sh (-2.09%)
Donald Yacktman 16,239,945 sh (-2.8%)
Ken Fisher 30,711,655 sh (-3.34%)
Ronald Muhlenkamp 36,364 sh (-3.35%)
Pioneer Investments 14,409,135 sh (-5.03%)
Vanguard Health Care Fund 31,600,488 sh (-5.34%)
Mario Gabelli 1,153,774 sh (-6.71%)
Charles Brandes 6,672,418 sh (-8.44%)
Steven Cohen 500,887 sh (-8.87%)
Michael Price 592,100 sh (-9.89%)
NWQ Managers 13,815,681 sh (-10.52%)
RS Investment Management 2,337,990 sh (-15.68%)
David Dreman 90,867 sh (-18.14%)
Alan Fournier 1,506,574 sh (-20.98%)
Ray Dalio 57,808 sh (-26.27%)
HOTCHKIS & WILEY 205,600 sh (-94.7%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 Add 57.8%0.23%$25.079 - $28.86 $ 29.37%6562712
Ray Dalio 2013-03-31 Reduce -26.27%0.01%$25.079 - $28.86 $ 29.37%57808
Ronald Muhlenkamp 2012-12-31 Reduce -89.46%1.7%$23.66 - $26.04 $ 29.317%37624
David Dreman 2012-12-31 Reduce -77.06%0.23%$23.66 - $26.04 $ 29.317%110998
Ray Dalio 2012-12-31 Add 73.45%0.01%$23.66 - $26.04 $ 29.317%78400
John Hussman 2012-09-30 Sold Out 0.43%$22.34 - $24.95 $ 29.323%0
David Dreman 2012-09-30 Reduce -34.04%0.13%$22.34 - $24.95 $ 29.323%483957
George Soros 2012-09-30 Reduce -69.36%0.12%$22.34 - $24.95 $ 29.323%165000
Ray Dalio 2012-09-30 Reduce -54.16%0.02%$22.34 - $24.95 $ 29.323%45200
Joel Greenblatt 2012-09-30 Add 40.57%0.02%$22.34 - $24.95 $ 29.323%44666
Lee Ainslie 2012-06-30 Sold Out 2.4%$21.42 - $23.21 $ 29.331%0
Charles Brandes 2012-06-30 Reduce -21.64%0.52%$21.42 - $23.21 $ 29.331%9367718
John Hussman 2012-06-30 Reduce -49.98%0.44%$21.42 - $23.21 $ 29.331%1001000
George Soros 2012-06-30 Reduce -32.27%0.08%$21.42 - $23.21 $ 29.331%538457
Ray Dalio 2012-06-30 New Buy0.03%$21.42 - $23.21 $ 29.331%98600
Richard Perry 2012-06-30 Sold Out 0.03%$21.42 - $23.21 $ 29.331%0
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Pfizer Inc

52-Week High Companies: PFE, D, PGN, FE
July 2, 2012
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs: Pfizer Inc. (PFE), Dominion Resources Inc. (D), Progress Energy Inc. (PGN) and FirstEnergy Corp. (FE). Read more...
52-Week High Companies: PFE, WFM, EW, CVS, COST
June 25, 2012
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs: Pfizer Inc. (PFE), Whole Foods Market Inc. (WFM), Edwards Lifesciences Corp. (EW), CVS Caremark Corp. (CVS) and Costco Wholesale Corp. (COST). Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 14.00
PFE's P/E(ttm) is ranked higher than
75% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.76 vs. PFE: 14.00 )
PFE' s 10-Year P/E(ttm) Range
Min: 9.46   Max: 209
Current: 14
9.46
209
P/B 2.59
PFE's P/B is ranked higher than
58% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. PFE: 2.59 )
PFE' s 10-Year P/B Range
Min: 1.32   Max: 20.43
Current: 2.59
1.32
20.43
P/S 3.78
PFE's P/S is ranked lower than
61% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. PFE: 3.78 )
PFE' s 10-Year P/S Range
Min: 1.72   Max: 10.81
Current: 3.78
1.72
10.81
PFCF 16.55
PFE's PFCF is ranked higher than
80% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. PFE: 16.55 )
PFE' s 10-Year PFCF Range
Min: 5.02   Max: 90.57
Current: 16.55
5.02
90.57
EV-to-EBIT 17.57
PFE's EV-to-EBIT is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.70 vs. PFE: 17.57 )
PFE' s 10-Year EV-to-EBIT Range
Min: 6.5   Max: 64.3
Current: 17.57
6.5
64.3
PEG 3.18
PFE's PEG is ranked higher than
83% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. PFE: 3.18 )
PFE' s 10-Year PEG Range
Min: 0.88   Max: 202.67
Current: 3.18
0.88
202.67
Shiller P/E 21.47
PFE's Shiller P/E is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.12 vs. PFE: 21.47 )
PFE' s 10-Year Shiller P/E Range
Min: 8.49   Max: 36.31
Current: 21.47
8.49
36.31

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 3.14
PFE's Dividend Yield is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. PFE: 3.14 )
PFE' s 10-Year Dividend Yield Range
Min: 0.71   Max: 10.4
Current: 3.14
0.71
10.4
Dividend Payout 0.5
PFE's Dividend Payout is ranked higher than
87% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.86 vs. PFE: 0.5 )
PFE' s 10-Year Dividend Payout Range
Min: 0.3   Max: 1.12
Current: 0.5
0.3
1.12
Dividend growth (3y) 2.4
PFE's Dividend growth (3y) is ranked higher than
90% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.95 vs. PFE: 2.4 )
PFE' s 10-Year Dividend growth (3y) Range
Min: -11.2   Max: 16.5
Current: 2.4
-11.2
16.5
Yield on cost (5-Year) 2.13
PFE's Yield on cost (5-Year) is ranked higher than
81% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. PFE: 2.13 )
PFE' s 10-Year Yield on cost (5-Year) Range
Min: 0.49   Max: 7.16
Current: 2.13
0.49
7.16
Share Buyback Rate -1.6
PFE's Share Buyback Rate is ranked higher than
70% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.00 vs. PFE: -1.6 )
PFE' s 10-Year Share Buyback Rate Range
Min: 2.3   Max: -12.7
Current: -1.6

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 10.7
PFE's Price/Net Current Asset Value is ranked higher than
70% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. PFE: 10.7 )
PFE' s 10-Year Price/Net Current Asset Value Range
Min: 7.1   Max: 53.5
Current: 10.7
7.1
53.5
Price/DCF (Projected) 1
PFE's Price/DCF (Projected) is ranked higher than
74% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. PFE: 1 )
PFE' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 2.4
Current: 1
0.7
2.4
Price/Median PS Value 1
PFE's Price/Median PS Value is ranked higher than
84% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.70 vs. PFE: 1 )
PFE' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 2.7
Current: 1
0.6
2.7
Price/Peter Lynch Fair Value 1.8
PFE's Price/Peter Lynch Fair Value is ranked lower than
65% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. PFE: 1.8 )
PFE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.9   Max: 8
Current: 1.8
0.9
8
Earnings Yield (Greenblatt) 5.70
PFE's Earnings Yield (Greenblatt) is ranked lower than
74% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. PFE: 5.70 )
PFE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 15.3
Current: 5.7
1.6
15.3
Forward Rate of Return (Yacktman) 11.23
PFE's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.82 vs. PFE: 11.23 )
PFE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.3   Max: 18.4
Current: 11.23
6.3
18.4

Business Description

Pfizer Inc. was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based global pharmaceutical company applying innovative science to improve world health. It discovers, develops, manufactures and markets prescription medicines for humans and animals. The company operates in two business segments: Biopharmaceutical and Diversified. Biopharmaceutical segment includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units, which include products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease and endocrine disorders, among others. Diversified segment includes Animal Health products that prevent and treat diseases in livestock and companion animals; Consumer Healthcare products that include over-the-counter health care products such as pain management therapies, cough/cold/allergy remedies, dietary supplements, hemorrhoidal care and personal care items; Nutrition products such as infant and toddler formula products; and Capsugel, which represents its gelatin capsules business. Biopharmaceutical segment includes products like Lipitor, Norvasc, Caduet, Chantix/Champix, Lyrica, Revati, Geodon/Zeldox, Aricept, Celebrex, Zyvox, Viagra, Detrol/Detrol LA, Sutent, Xalatan, Genotropin, Vfend, Effexor, Prevnar/Prevnar7, Enbrel, Zosyn (Tazocin internationally), Premarin, Hemophilia, Protonix and Spiriva. Diversified segment includes Animal Health unit, in which the Company discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals, and Consumer Healthcare, Nutirition and Capsugel, which is a product line that includes not only hard gelatin capsules, but also liquid, softgel, non-animal, and fish gelatin capsules, all for use in pharmaceutical and dietary supplement dosage delivery. The products are sold around the world under brand-name, logo and certain product design trademarks. Raw materials essential to the company's businesses are purchased worldwide in the ordinary course of business from numerous suppliers. In general, these materials are available from multiple sources. The Company is subject to regulated by national, state and local agencies.
Company Website
SEC Reports
Industry: Drug Manufacturers - Major
Compare:GSK, JNJ, RHHBY, NVS, ABT
Traded in other countries:PFZ.UK, PFEBC.Belgium, PFE.Sweden, PFE.Switzerland, PFE.Germany
ยป More Articles for PFE

Headlines

Articles On GuruFocus.com
20 Mega Caps and Their Dividend Payments and Which to Consider May 17 2013 
3 Dogs of the Dow With Highest Earnings Growth Apr 27 2013 
100 Most-Sold Stocks by Famous Investment Gurus Apr 11 2013 
20 Best-Yielding Health Care Stocks - Less Volatile Than the Market Apr 02 2013 
3 Dogs of the Dow with the Highest Expected Earnings Growth Mar 27 2013 
10 Best Dividend Paying Drug Manufacturing Stocks Mar 02 2013 
My 3 Favorite Dogs of the Dow Jones Feb 26 2013 
Why I Want You to Take an Axe to Your Dividend Stock Portfolio Feb 06 2013 
2013: Breakout or Comeuppance? Jan 28 2013 
The Best Dogs of the Dow Jones as of December 2012 Dec 26 2012 

More From Our Partners
Stocks Rally as Bernanke Defends Aggressive Fed Easing May 22 2013 - FOXBUSINESS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial